Eastern Cooperative Oncology Group 4402: Rituximab Extended Schedule of Retreatment Trial (RESORT)

Clinical Lymphoma and Myeloma

Volumn 6, Issue 5, 2006, Pages 423-426

  Kahl, Brad S ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Clinical trials; Immunotherapy; Non Hodgkin's lymphoma; Quality of life

Indexed keywords

RITUXIMAB;

ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CORRELATIONAL STUDY; DISEASE COURSE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; HUMAN; IMMUNOTHERAPY; MAINTENANCE THERAPY; NONHODGKIN LYMPHOMA; QUALITY OF LIFE; RANDOMIZATION; RETREATMENT; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT PLANNING;

EID: 33646590955     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2006.n.024     Document Type: Article

References (20)

1. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti CD-20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-2833,
2. Davis TA, White CA, Grillo-Lopez AJ, et al. Single-agent: monoclonal anti-body efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999; 17:1851-1857,
3. Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkids lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18:3135-3143.
4. Foran JM, Rohatiner AZS, Cunningham D, et al. European phase II study of rituximab for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphorna, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18:317-324.
5. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with low rumor burden: clinical and molecular evaluation. Blood 2001; 97:101-106.
6. Witzig TE, Vukov AM, Habermann TM, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkn's lymphorna: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005; 23:1103-1108.
7. Conconi A, Martinelli G, Thieblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003; 102:2741-2745.
8. Coiffier B, Ketterer N, Haioun C, et al. A multicenter, randomized phase II study of rituximab at two dosages in patients with relapsed or refractory intermediate or high grade NHL or in elderly patients in first line therapy. Blood 1997; 90:510a (Abstract #2271).
9. Piro LD, White CA, Grillo-López AJ, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkidn's lymphorna. Ann Oncol 1999; 10:655-661.
10. Hainsworth JD, Litchy S, Burris HA, et al. Rituximab as first line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:4261-4267.
11. Ghielmini M, Schmitz SFH, Cogliatti S, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with die standard weekly x 4 schedule. Blood 2004; 103:4416-4423.
12. Hainsworth JD, Litchy S, Barron JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003; 21:1746-1751.
13. Hainsworth JD, Litchy S, Schaffer DW, et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus retreatment at progression in patients with indolent non-Hodgkin's lymphoma-a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005; 23:1088-1095,
14. Webster K, Cella D. Quality of life in patients with low-grade non-Hodgkin's lymphoma. Oncology 1998; 12:697-714.
15. Stabler B, Berkowitz LR, Schell MJ, et al. Quality of life in patients treated with rituximab as a single agent. Proc Am Soc Clin Oncol 2002; 21:205b (Abstract #2639).
16. Solal-Celigny P. Lepage E, Brousse N, et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 trial. J Clin Oncol 1998; 16:2332-2338.
17. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002; 29:2-9.
18. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:3262-3269.
19. Gordan LN, Grow WB, Pusateri A, et al. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 2005; 23:1096-1102.
20. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9:995-1001.